YorkBridge Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

YorkBridge Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-704	Closed	-$92K	–	723
2019 Q2	$92K	Buy	704 +8	+1%	+$1.03K	0.04%	300
2019 Q1	$94K	Buy	696 +93	+15%	+$11.6K	0.04%	288
2018 Q4	$59K	Sell	603 -111	-16%	-$13.1K	0.03%	316
2018 Q3	$98K	Sell	714 -792	-53%	-$99.3K	0.04%	288
2018 Q2	$187K	Hold	1,506	–	–	0.08%	182
2018 Q1	$168K	Buy	1,506 +31	+2%	+$3.71K	0.08%	201
2017 Q4	$166K	Buy	1,475 +84	+6%	+$10.2K	0.08%	199
2017 Q3	$195K	Sell	1,391 -34	-2%	-$4.62K	0.1%	176
2017 Q2	$173K	Buy	1,425 +982	+222%	+$114K	0.09%	187
2017 Q1	$59K	Buy	443 +20	+5%	+$2.58K	0.03%	353
2016 Q4	$50K	Buy	+423	New	+$51.8K	0.03%	353

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

YorkBridge Wealth Partners's ALXN Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 704 shares — an estimated $92K sold.

YorkBridge Wealth Partners first reported a position in ALXN in Q4 2016 and held it in 11 quarters. The position peaked at $195K in Q3 2017. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

YorkBridge Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 704 Alexion Pharmaceuticals shares in Q3 2019, an estimated $92K.
YorkBridge Wealth Partners first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 11 quarters.
YorkBridge Wealth Partners's Alexion Pharmaceuticals position peaked at $195K in Q3 2017.
648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.